Fibralign Corporation is a Stanford University spin-out that produces advanced therapeutic biomedical devices, utilizing its powerful patented Nanoweave® technology for creating 3D scaffolding which precisely mimics human tissue structure. This technology has been proven to directly influence desired cell behavior for repairing diseased tissue and can be further utilized as a “bioreactor” providing sustained localized delivering of cells and gene therapy for precisely targeting therapy. Fibralign has launched it's first product the BioBridge® Collagen Matrix for the treatment of secondary lymphedema, a global chronic and disfiguring disease that currently has no cure. Fibralign has been recognized for its innovation and has benefited from being part of prominent healthcare accelerated programs. These include:  Overall winner of the prestigious MedTech Innovator Award (1st out of over 400 startups) - https://www.linkedin.com/company/medtech-innovator/  Winner of West Coast BioSciKin startup competition in 2016 (1st out of >150 startups) - https://califesciences.org/bioscikin-1/  Founding cohort of JLABS@SSF - https://jlabs.jnjinnovation.com/locations/jlabs-ssf  StartX Med – Stanford start-up community for healthcare companies (Acceptance rate < 8%) https://www.linkedin.com/company/startx-/  Named a 2021 UCSF Rosenman Institute Innovator